Endotoxin Antagonists

  • David L. Dunn

Abstract

Over the last several decades our ability to prolong life and treat diseases once thought incurable has increased considerably. However, concurrent with the advent of new biotechnologic, medical, and surgical approaches to the treatment of a variety of complex disease processes has come the recognition that our abilities remain finite. In particular, infection continues to represent a substantial cause of morbidity and mortality in all groups of patients, and many of the new therapeutic modalities (e.g., cancer chemotherapy, solid organ and bone marrow transplantation, intensive care unit treatment) are associated with significantly increased rates and previously unrecognized infections.

Keywords

Placebo Polysaccharide Pancreatitis Stratification Pseudomonas 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dunn DL: Gram-negative bacterial sepsis and sepsis syndrome. Surg Clin North Am 1994; 74: 621–635.PubMedGoogle Scholar
  2. 2.
    Anonymous: Center for Disease Control: increase in national hospital discharge survey rates for septicemia—United States, 1979-1987. JAMA 1990; 263: 937-938.Google Scholar
  3. 3.
    Burd RS, Cody CS, Dunn DL: Immunotherapy of Gram-Negative Bacterial Sepsis. Austin, TX, Medical Intelligence Unit, R.G. Landes, 1992Google Scholar
  4. 4.
    Battafarano RJ, Dunn DL: Immunotherapy in critically ill patients. In: Chernow BC (ed) The Pharmalologic Approach to the Critically 111 Patient. Baltimore, Williams & Wilkins, 1994; 365–378.Google Scholar
  5. 5.
    Cody CS, Dunn DL: Endotoxins in septic shock. In: Neugebauer E, Holaday J (eds) GRC Handbook of Mediators in Septic Shock. Boca Raton, FL, CRC Press, 1993; l–37.Google Scholar
  6. 6.
    Leeson MC, Fujihara Y, Morrison DC: Evidence for lipopolysaeeharide as the predominant proinflammatory mediator in supernatants of antibiotic-treated bacteria. Infect Immun 1994; 62: 4975–4980.PubMedGoogle Scholar
  7. 7.
    Morrison DC: Antibiotic-mediated release of endotoxin and the pathogenesis of gram-negative sepsis. Prog Clin Biol Res 1998; 397: 199–207.PubMedGoogle Scholar
  8. 8.
    Hesse DG, Tracey KJ, Fong Y, et al: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166: 147–153.PubMedGoogle Scholar
  9. 9.
    Fong Y, Moldawer LL, Shires GT, Lowry SF: The biologic characteristics of cytokines and their implication in surpcal injury. Surg Gynecol Obstet 1990; 170: 363–378.PubMedGoogle Scholar
  10. 10.
    Rietschel ET, Kirikae T, Schade FU, et al: Bacterial endotoxin: molecular relationships of structure of activity and function. FASEBJ 1994; 8: 217–225.Google Scholar
  11. 11.
    Raetz CR: Biochemistry of endotoxins. Annu Rev Biochem 1990; 59: 129–170.PubMedCrossRefGoogle Scholar
  12. 12.
    Muller-Loennies S, Zahringer U, Seydel U, Kusumoto S, Ulmer AJ, Rietschel ET: What we don’t know about the chemical and physical structure of lipopolysaccharide in relation to biological activity. Prog Clin Biol Res 1998; 397: 51–72.PubMedGoogle Scholar
  13. 13.
    Han J, Brown T, Beutler B: Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J Exp Med 1990; 151: 101–114.Google Scholar
  14. 14.
    Raetz C, Ulevitch R, Wright S, Sibley C, Ding A, Nathan C: Gram negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEBJ 1991; 5: 2652–2660.Google Scholar
  15. 15.
    Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD 14: a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1429–1431.PubMedCrossRefGoogle Scholar
  16. 16.
    Ferrero E, Jiao D, Tsuberi BZ, et al: Transgenic mice expressing human CD 14 are hypersensitive to lipopolysaccharide. Proc Natl Acad Sci USA 1993; 90: 2380–2384.PubMedCrossRefGoogle Scholar
  17. 17.
    Wright SD, Detmers PA, Aida Y, et al: CD 18 deficient cells respond to lipopolysaccharide in vitro. J Immunol 1990; 144: 2566–2571.PubMedGoogle Scholar
  18. 18.
    Hampton R, Golenbock D, Penman M, Krieger M, Raetz C: Recognition and plasma clearance of endotoxin by scavenger receptors. Nature 1991; 352: 342–344.PubMedCrossRefGoogle Scholar
  19. 19.
    Morrison DC, Kirikae T, Lei MG, Chen T, Vukajlovich SW: The receptor(s) for endotoxin on mammalian cells. Prog Clin Biol Res 1994; 388: 3–15.PubMedGoogle Scholar
  20. 20.
    Tobias PS, Soldau K, Gegner JA, Mintz D, Ulevitch RJ: lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD 14. J Biol Chem 1995; 270: 10482–10488.PubMedCrossRefGoogle Scholar
  21. 21.
    Lee JD, Kato K, Tobias PS, Kirkland TN, Ulevitch RJ: Transfection of CD 14 into 70Z/3 cells dramatically enhances the sensitivity to complexes of lipopolysaccharide (LPS) and LPS binding protein. J Exp Med 1992; 175: 1697–1705.PubMedCrossRefGoogle Scholar
  22. 22.
    Schletter J, Brade H, Brade L, et al: Binding of lipopolysaccharide (LPS) to an 80-kilodalton membrane protein of human cells is mediated by soluble CD 14 and LPS-binding protein. Infect Immun 1995; 63: 2576–2580.PubMedGoogle Scholar
  23. 23.
    Haziot A, Rong GW, Silver J, Goyert SM: Recombinant soluble CD 14 mediates the activation of endothelial cells by lipopolysaccharide. J Immunol 1993; 151: 1500–1507.PubMedGoogle Scholar
  24. 24.
    Landman R, Zimmerli W, Sansano S, et al: Increased circulating soluble CD 14 is associated with high mortality in gram-negative septic shock. J Infect Dis 1995; 171: 639–644.CrossRefGoogle Scholar
  25. 25.
    Battafarano RJ, Burd RS, Kurrelmeyer KM, Ratz CA, Dunn DL: Inhibition of splenic macrophage tumor necrosis factor-α secretion in vivo by antilipopolysaccharide monoclonal antibodies. Arch Surg 1994; 129: 179–186.PubMedCrossRefGoogle Scholar
  26. 26.
    Hack CE, Aarden LA, Thijs LG: Role of cytokines in sepsis. Adv Immunol 1997; 66: 101–195.PubMedCrossRefGoogle Scholar
  27. 27.
    Banner DW, D’Arcy A, Janes W, et al: Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73: 431–445.PubMedCrossRefGoogle Scholar
  28. 28.
    Giri JG, Wells J, Dower SK, et al: Elevated levels of shed type II IL-1 receptor in sepsis: potential role for type II receptor in regulation of IL-1 responses. J Immunol 1994; 153: 5802–5809.PubMedGoogle Scholar
  29. 29.
    Porteu F, Nathan CF: Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990; 172: 599–607.PubMedCrossRefGoogle Scholar
  30. 30.
    Aderka D: The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996; 7: 231–240.PubMedCrossRefGoogle Scholar
  31. 31.
    Pruitt J, Copeland E, Moldawer L: Interleukin-1 and interleukin-1 antagonism in sepsis systemic inflammatory response syndrome and septic shock. Shock 1995; 3: 235–251.PubMedCrossRefGoogle Scholar
  32. 32.
    Goldie AS, Fearon KC, Ross JA, et al: Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome: the Sepsis Intervention Group. JAMA 1995; 274: 172–177.PubMedCrossRefGoogle Scholar
  33. 33.
    Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470–474.PubMedCrossRefGoogle Scholar
  34. 34.
    Beutler B, Milsark IW, Cerami AG: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 1985; 299: 867–869.Google Scholar
  35. 35.
    Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662–664.PubMedCrossRefGoogle Scholar
  36. 36.
    Mohler KM, Torrance DS, Smith CA, et al: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548–1561.PubMedGoogle Scholar
  37. 37.
    Fischer E, Marano MA, VanZee KJ, et al: Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89: 1551–1557.PubMedCrossRefGoogle Scholar
  38. 38.
    Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550–552.PubMedCrossRefGoogle Scholar
  39. 39.
    Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1: 355–357.PubMedCrossRefGoogle Scholar
  40. 40.
    Cannon JG, Tompkins RG, Gelfand JA, et al: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79–84.PubMedCrossRefGoogle Scholar
  41. 41.
    Shapira L, Takashiba S, Champagne C, Amar S, Van Dyke TE: Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNFα and IL-1β production by human monocytes. J Immunol 1994; 153: 1818–1824.PubMedGoogle Scholar
  42. 42.
    Dunn DL, Mach PA, Cerra FB: Monoclonal antibodies protect against lethal effects of gram-negative bacterial sepsis. Surg Forum 1983; 34: 142–144.Google Scholar
  43. 43.
    Dunn DL, Bogard WC, Cerra FB: Efficacy of type-specific and cross-reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis. Surgery 1985; 98: 283–290.PubMedGoogle Scholar
  44. 44.
    McCabe WR, Kreger BE, Johns M: Type-specific and crossreactive antibodies in gram-negative bacteremia. N Engl J Med 1972; 287: 261–267.PubMedCrossRefGoogle Scholar
  45. 45.
    Zinner SH, McCabe WR: Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli. J Infect Dis 1976; 133: 37–45.PubMedCrossRefGoogle Scholar
  46. 46.
    Dunn DL, Bogard WC, Cerra FB: Enhanced survival during murine gram-negative bacterial sepsis by use of a murine monoclonal antibody. Arch Surg 1985; 120: 50–53.PubMedCrossRefGoogle Scholar
  47. 47.
    Dunn DL, Ewald DP, Chandan N, Cerra FB: Immunotherapy of gram-negative bacterial sepsis: a single murine monoclonal antibody provides cross-genera protection. Arch Surg 1986; 121: 58–62.PubMedCrossRefGoogle Scholar
  48. 48.
    Dunn DL, Priest BP, Condie RM: Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis. Arch Surg 1988; 123: 1389–1393.PubMedCrossRefGoogle Scholar
  49. 49.
    Kirkland TN, Colwell DE, Michalek SM, McGhee JR, Ziegler EJ: Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies. J Immunol 1986; 137: 3614–3619.PubMedGoogle Scholar
  50. 50.
    Teng NN, Kaplan HS, Hebert JM, et al: Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 1985; 82: 1790–1794.PubMedCrossRefGoogle Scholar
  51. 51.
    Mayoral JL, Dunn DL: Cross-reactive murine monoclonal antibodies directed against the core/lipid A region of endotoxin inhibit production of tumor necrosis factor. J Surg Res 1990; 49: 287–292.PubMedCrossRefGoogle Scholar
  52. 52.
    Cody CS, Burd RS, Mayoral JL, Dunn DL: Protective antilipopolysaccharide monoclonal antibodies inhibit tumor necrosis factor production. J Surg Res 1992; 52: 314–319.PubMedCrossRefGoogle Scholar
  53. 53.
    Dunn DL, Bogard WC, Cerra FB: Efficacy of type specific and cross-reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis. Surgery 1985; 98: 283–290.PubMedGoogle Scholar
  54. 54.
    Gray BH, Haseman JR: Bactericidal activity of synthetic peptides based on the structure of the 55-kilodalton bactericidal protein from human neutrophils. Infect Immun 1994; 62: 2732–2739.PubMedGoogle Scholar
  55. 55.
    Kohn FR, Ammons WS, Horwitz A, et al: Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability-increasing protein in experimental endotoxemia. J Infect Dis 1993; 168: 1307–1310.PubMedCrossRefGoogle Scholar
  56. 56.
    Evans TJ, Carpenter A, Moyes D, Martin R, Cohen J: Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram-negative sepsis. J Infect Dis 1995; 171: 153–160.PubMedCrossRefGoogle Scholar
  57. 57.
    Kelly CJ, Cech AC, Argenteanu M, et al: Role of bactericidal/permeability-increasi protein in the treatment of gram-negative pneumonia. Surgery 1993; 114: 140–146.PubMedGoogle Scholar
  58. 58.
    Aketagawa J, Miyata T, Ohtsubo S, et al: Primary structure of Iimulus anticoagulant anti-lipopolysaccharide factor. J Biol Chem 1986; 261: 7357–7365.PubMedGoogle Scholar
  59. 59.
    Desch C, O’Hara P, Harlan J: Antilipopolysaccharide factor from horseshoe crab, Tachypleus tridentatus, inhibits lipopolysaccharide activation of cultured human endothelial cells. Infect Immun 1989; 57: 1612–1614.PubMedGoogle Scholar
  60. 60.
    Alpert G, Baldwin G, Thompson C, et al: Limulus antilipopoly saccharide factor protects rabbits from meningococcal endotoxin shock. J Infect Dis 1992; 165: 494–500.PubMedCrossRefGoogle Scholar
  61. 61.
    Warren HS, Glennon ML, Wainwright N, et al: Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor. Infect Immun 1992; 60: 2506–2513.PubMedGoogle Scholar
  62. 62.
    Roth RI, Su D, Child AH, Wainwright NR, Levin J: Iimulus antilipopolysaccharide factor prevents mortality late in the course of endotoxemia. J Infect Dis 1998; 177: 388–394.PubMedCrossRefGoogle Scholar
  63. 63.
    Hoess A, Watson S, Siber GR, Iiddington R: Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab. Limulus anti-LPS factor, at 1.5Å resolution. EMBOJ 1993; 12: 3351–3356.Google Scholar
  64. 64.
    Theofan G, Horwitz AH, Williams RE, et al: An amino-terminal fragment of human lipopolysaccharide-binding protein retains lipid A binding but not CD14-stimulatory activity. J Immunol 1994; 152: 3623–3629.PubMedGoogle Scholar
  65. 65.
    Gallay P, Heumann D, Le Roy D, Barras C, Glauser MP: Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc Natl Acad Sci USA 1994; 91: 7922–7926.PubMedCrossRefGoogle Scholar
  66. 66.
    Han J, Bohuslav J, Jiang Y, et al: CD 14 dependent mechanisms of cell activation. Prog Clin Biol Res 1998; 397: 157–168.PubMedGoogle Scholar
  67. 67.
    Haziot A, Borg GW, Iin XY, Silver J, Goyert SM: Recombinant soluble CD 14 prevents mortality in mice treated with endotoxin (lpopolysaecharide). J Immunol 1995; 154: 6529–8532.PubMedGoogle Scholar
  68. 68.
    Schimke J, Mathison J, Morgiewicz J, Uleviteh RJ: Anti-CD 14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci USA 1998; 95: 13875–13880.PubMedCrossRefGoogle Scholar
  69. 69.
    Beamer LJ, Carroll SF, Eisenberg D: The BPI/LBP family of proteins: a structural analysis of conserved regions. Protein Sci 1998; 7: 906–914.PubMedCrossRefGoogle Scholar
  70. 70.
    Elsbach P: The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J Leukocyte Biol 1998; 64: 14–18.PubMedGoogle Scholar
  71. 71.
    Battafarano RJ, Dahlberg PS, Ratz CA, et al: Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induc tumor necrosis factor-αa secretion in vitro. Surgery 1995; 118: 318–324.CrossRefGoogle Scholar
  72. 72.
    Kellogg TA, Weiss CA, Johnston JW, Wasiluk KR, Dunn DL: Antiendotoxin agents share molecular homology within their lipopolysaccharide binding domains. J Surg Res 1999; 85: 136–141.PubMedCrossRefGoogle Scholar
  73. 73.
    Kim SK, Battafarano RJ, Dahlberg PS, Dunn DL: Protective effect of monophosphoryl lipid A (MPLA) during systemic candidiasis in neutropenic and normal mice. Surg Forum 1993; 44: 37–38.Google Scholar
  74. 74.
    Chase JJ, Kubey W, Dulek MH, et al: Effect of monophosphoryl lipid A on host resistance to bacterial infection. Infect Immun 1986; 53: 711–712.PubMedGoogle Scholar
  75. 75.
    Field SK, Morrison DC: An anti-idiotype antibody which mimics the inner-core region of lipopolysaccharide protects mice against a lethal challenge with endotoxin. Infect Immun 1994; 62: 3994–3999.PubMedGoogle Scholar
  76. 76.
    Battafarano RJ, Dahlber PS, Uknis ME, et al: A monoclonal antibody designed to mimic LPS binds to the macrophage cell surface and inhibits lipopolysaccharide-induced TNFα secretion in vitro. J Immunol (submitted)Google Scholar
  77. 77.
    Bone RC: Let’s agree on terminology: definitions of sepsis. Crit Care Med 1991; 19: 973–976.PubMedCrossRefGoogle Scholar
  78. 78.
    Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee; American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644–1655.PubMedCrossRefGoogle Scholar
  79. 79.
    Bossink AW, Groeneveld J, Hack CE, Thijs LG: Prediction of mortality in febrile medical patients: how useful are systemic inflammatory response syndrome and sepsis criteria? Chest 1998; 113: 1533–1541.PubMedCrossRefGoogle Scholar
  80. 80.
    Ziegler EJ, Fisher CJ Jr, Sprung CL, et al: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial: the HA-1A Sepsis Study Group. N Engl J Med 1991; 324: 429–436.PubMedCrossRefGoogle Scholar
  81. 81.
    Greenman RL, Schein RM, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266: 1097–1102.PubMedCrossRefGoogle Scholar
  82. 82.
    McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR: Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial; CHESS Trial Study Group. Ann Intern Med 1994; 121: 1–5.PubMedGoogle Scholar
  83. 83.
    Bone RC, Balk RA, Fein AM, et al: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial; the E5 Sepsis Study Group. Crit Care Med 1995; 23: 994–1005.PubMedCrossRefGoogle Scholar
  84. 84.
    Baumgartner JD: Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal. Infect Dis Clin N Am 1991; 5: 915–927.Google Scholar
  85. 85.
    Warren HS, Amato SF, Fitting C, et al: Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide, J Exp Med 1993; 177: 89–97.PubMedCrossRefGoogle Scholar
  86. 86.
    Fujihara Y, Lei MG, Morrison DC: Characterization of specific binding of a human immunoglobulin M monoclonal antibody to lipopolysaccharide and its lipid A domain. Infect Immun 1993; 61: 910–918.PubMedGoogle Scholar
  87. 87.
    Munster AM, Winchurch RA, Thupari JN, Ernst CB: Reversal of postburn immunosuppression with low-dose polymyxin B. J Trauma 1986; 26: 995–998.CrossRefGoogle Scholar
  88. 88.
    Nakamura T, Suzuki Y, Shimada N, Ebihara I, Shoji H, Koide H: Hemoperfusion with polymyxin B-immobilized fiber attenuates the increased plasma levels of thrombomodulin and von Willebrand factor from patients with septic shock. Blood Purif 1998; 16: 179–186.PubMedCrossRefGoogle Scholar
  89. 89.
    Willatts SM, Radford S, Leitermann M: Effect of the antiendotoxin agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial. Crit Care Med 1995; 23: 1033–1039.PubMedCrossRefGoogle Scholar
  90. 90.
    Fisher CJ Jr, Opal SM, Dhainaut JF, et al: Influence of an antitumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis: the CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21: 318–327.PubMedCrossRefGoogle Scholar
  91. 91.
    Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. JAMA 1995; 273: 934–941.PubMedCrossRefGoogle Scholar
  92. 92.
    Fisher CJ Jr, Slotman GJ, Opal SM, et al: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial; the IL-1RA Sepsis Syndrome Study Group. Crit Care Med 1994; 22: 12–21.PubMedGoogle Scholar
  93. 93.
    Fisher CJ Jr, Dhainaut JF, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial; phase III rhIL-lra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836–1843.PubMedCrossRefGoogle Scholar
  94. 94.
    Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein; the Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697–1702.PubMedCrossRefGoogle Scholar
  95. 95.
    Abraham E, Glauser MP, Butler T, et al: A p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial; Ro 45-2081 Study Group. JAMA 1997; 277: 1531–1538.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • David L. Dunn

There are no affiliations available

Personalised recommendations